Clinical Trial Update: A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related) [Phase 1]

View source ↗

Summary

Sarepta's Phase 1 gene transfer study SRP-6004 in ambulatory participants with limb-girdle muscular dystrophy type 2B (DYSF-related) has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Limb-girdle Muscular Dystrophy Type 2b

Drugs mentioned

• SRP-6004

Snippet

Sponsor: Sarepta Therapeutics, Inc. | Conditions: Limb Girdle Muscular Dystrophy | Phase 1 | Status: TERMINATED